Wellington Management Group LLP Lowers Position in Aurinia Pharmaceuticals Inc $AUPH

Wellington Management Group LLP lessened its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 9.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 55,190 shares of the biotechnology company’s stock after selling 5,561 shares during the quarter. Wellington Management Group LLP’s holdings in Aurinia Pharmaceuticals were worth $444,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 33.9% in the 1st quarter. American Century Companies Inc. now owns 229,734 shares of the biotechnology company’s stock valued at $1,847,000 after purchasing an additional 58,144 shares during the period. Fox Run Management L.L.C. lifted its stake in shares of Aurinia Pharmaceuticals by 122.7% in the 1st quarter. Fox Run Management L.L.C. now owns 44,962 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 24,777 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 1,289.3% in the 1st quarter. Russell Investments Group Ltd. now owns 77,843 shares of the biotechnology company’s stock valued at $626,000 after purchasing an additional 72,240 shares during the period. Nuveen LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter valued at approximately $10,014,000. Finally, Virtu Financial LLC lifted its stake in shares of Aurinia Pharmaceuticals by 38.2% in the 1st quarter. Virtu Financial LLC now owns 14,727 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 4,074 shares during the period. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on AUPH. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Royal Bank Of Canada raised their price objective on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.00.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang bought 200,000 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, August 5th. The stock was acquired at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the acquisition, the director owned 11,329,500 shares in the company, valued at approximately $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders acquired 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Stock Down 0.7%

AUPH stock opened at $11.99 on Tuesday. Aurinia Pharmaceuticals Inc has a twelve month low of $6.42 and a twelve month high of $12.53. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The firm has a market cap of $1.58 billion, a PE ratio of 27.88 and a beta of 1.26. The business has a 50 day moving average of $9.98 and a 200 day moving average of $8.71.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). The company had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.